Telomir Pharms Stock Price, News & Analysis

Telomir Pharmaceuticals (NASDAQ:TELO) reported preclinical in vivo data (mice with aggressive human prostate tumors) showing oral Telomir-1 reduced DNA methylation of CASP8 and GSTP1 versus vehicle and chemotherapy at Day 10 and Day 21.

Telomir-1 produced a progressive, sustained methylation decrease through Day 21, while Rapamycin's early Day 10 effect partially rebounded by Day 21. Chemotherapy alone did not lower methylation. Combination Telomir-1 + chemotherapy showed lower methylation than chemotherapy alone.

Telomir Pharmaceuticals (NASDAQ:TELO) executed a binding LOI to acquire TELI Pharmaceuticals and consolidate worldwide rights to Telomir-1, converting each TELI share into TELO stock with an exchange ratio set by independent valuation. The deal includes up to $5 million in potential shareholder contributions: $1M at closing, $2M on IND acceptance, $2M at Phase 1/2 start. Closing is subject to shareholder approval, regulatory and diligence conditions; TELI shareholders face a six-month lockup. Telomir-1 has multiple preclinical signals across oncology, AMD, metabolic and aging models, and unified rights aim to enable global partnerships and out-licensing across larger ex-U.S. markets.

Telomir Pharmaceuticals (NASDAQ:TELO) reported new preclinical laboratory data on October 14, 2025 showing that Telomir-1 produces a concentration-dependent reduction in survival and mitochondrial activity of human pancreatic cancer (PANC-1) cells.

Effects were partially reversed by iron re-addition, implying iron-dependent mechanisms plus additional metabolic or epigenetic pathways. Telomir plans expanded preclinical studies, in vivo validation, and continued Investigational New Drug (IND) preparation.

Telomir Pharmaceuticals (NASDAQ:TELO) reported preclinical findings on October 9, 2025 showing Telomir-1 selectively reduces viability of aggressive triple-negative breast cancer (TNBC) cells in dose-dependent laboratory studies. The compound impaired cellular energy and mitochondrial function and caused cell death via an iron-dependent mechanism; cell viability recovered when iron was restored, supporting a defined mechanism linked to Jumonji domain histone demethylases (KDM5A/B, KDM6B). Telomir plans additional cancer models, animal studies, and IND-enabling work. The release notes TNBC represents 10–15% of breast cancers, with metastatic five-year survival around 12–15% and median overall survival ~11–13 months.

Telomir Pharmaceuticals (NASDAQ:TELO) reported preclinical results dated October 7, 2025 showing its candidate Telomir-1 reset DNA methylation and reactivated tumor suppressor genes MASPIN and RASSF1A in aggressive prostate cancer models.

Key findings: dose-dependent reduction in RASSF1A methylation, reversal of chemotherapy-induced MASPIN hypermethylation, ~50% tumor volume reduction in vivo, and elimination of chemotherapy-related mortality in the reported models. Telomir-1 also showed prior preclinical effects on STAT1, CDKN2A, histone demethylases, mitochondrial function, and telomere/epigenetic markers. Telomir is advancing Telomir-1 into IND-enabling preclinical studies.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced significant new in vitro data for its lead compound Telomir-1, revealing its ability to inhibit KDM5 family members, adding to its previously known KDM2/KDM6 and DNA methylation activity.

The breakthrough demonstrates Telomir-1's potential as a first-in-class broad-spectrum epigenetic reset therapy. The compound targets both histone demethylases and DNA methylation, key mechanisms in cancer progression and aging. In previous studies, Telomir-1 showed greater activity than chemotherapy and rapamycin in reducing abnormal DNA methylation and reactivating tumor suppressors.

The company is currently advancing IND-enabling studies and GMP scale-up for Telomir-1, with ongoing preclinical evaluations in aggressive cancers and aging models.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced significant preclinical data showing that its drug candidate Telomir-1 effectively resets DNA methylation to reactivate CDKN2A, a crucial tumor suppressor gene, in aggressive prostate cancer cells. The study demonstrated that Telomir-1 outperformed both Rapamycin and chemotherapy in inhibiting CDKN2A DNA methylation.

The findings build upon previous research showing Telomir-1's ability to reset STAT1, suggesting the drug can broadly reverse cancer-induced silencing of key tumor suppressors through two mechanisms: controlling unchecked cell growth and preventing immune evasion. The company is advancing its pre-IND program with ongoing CMC activities and IND-enabling studies, positioning Telomir-1 as a potential first-in-class longevity drug candidate targeting both cancer and aging.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced new in vitro data for its lead drug candidate, Telomir-1, revealing its potential as a first-in-class epigenetic therapy. The drug demonstrates potent inhibition of UTX (KDM6A), an enzyme crucial for DNA methylation and gene regulation.

The studies, conducted by Eurofins Discovery, show that Telomir-1 can effectively block multiple epigenetic enzymes including FBXL10, FBXL11, and JMJD3, while maintaining selectivity by not affecting GCN5L2. The drug also exhibits low-level inhibitory activity against Tankyrases, potentially disrupting cancer growth pathways without causing telomere-related toxicity.

This breakthrough suggests Telomir-1's potential applications in treating cancer, autoimmune disorders, neurodegeneration, autism spectrum disorder, metabolic dysfunction, and age-related diseases by resetting faulty DNA methylation patterns and restoring proper gene control.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced groundbreaking preclinical data showing that its lead compound Telomir-1 effectively inhibits three key histone demethylase enzymes: JMJD3, FBXL10, and FBXL11. These enzymes are crucial regulators of gene expression and are implicated in various diseases.

The study, conducted with Eurofins Discovery, demonstrates Telomir-1's potential to treat multiple conditions through epigenetic modulation, including cancer, autoimmune disorders, neurodegeneration, and metabolic dysfunction. The compound has shown superior performance compared to Paclitaxel and Rapamycin in preclinical cancer models, particularly in reactivating tumor suppressor genes.

The company is advancing Telomir-1's development and plans to finalize its first IND-enabling program, marking a significant step toward clinical trials.